GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (NSE:NATCOPHARM) » Definitions » Net Income

Natco Pharma (NSE:NATCOPHARM) Net Income : ₹13,883 Mil (TTM As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Natco Pharma's Net Income for the three months ended in Mar. 2024 was ₹3,863 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was ₹13,883 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Natco Pharma's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₹21.57.


Natco Pharma Net Income Historical Data

The historical data trend for Natco Pharma's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natco Pharma Net Income Chart

Natco Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,608.00 4,409.00 1,700.00 7,153.00 13,883.00

Natco Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,758.00 4,203.00 3,690.00 2,127.00 3,863.00

Natco Pharma Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Natco Pharma's Net Income for the fiscal year that ended in Mar. 2024 is calculated as

Net Income(A: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=16735+-2852+0+0
=13,883

Natco Pharma's Net Income for the quarter that ended in Mar. 2024 is calculated as

Net Income(Q: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=4776+-913+0+0
=3,863

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹13,883 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Natco Pharma  (NSE:NATCOPHARM) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Natco Pharma's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Natco Pharma Net Income Related Terms

Thank you for viewing the detailed overview of Natco Pharma's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Natco Pharma (NSE:NATCOPHARM) Business Description

Traded in Other Exchanges
Address
Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.

Natco Pharma (NSE:NATCOPHARM) Headlines

No Headlines